CCL17 and primary cutaneous T-cell non-Hodgkin lymphoma: It is noteworthy that the high expression of CCL17 in CTCL is significantly different from psoriasis vulgaris, suggesting that it may serve as a potential biomarker for the differential diagnosis, disease monitoring, and treatment response assessment of CTCL [31,53].